As of October 10, 2008, there were 122,315,635 shares of Insmed common stock outstanding. The reverse stock split would affect all Insmed common stock and stock options outstanding immediately prior to the effective time of the reverse stock split, if approved.
Insmed Inc. is a biopharmaceutical company with unique protein process development and manufacturing experience and a proprietary protein platform aimed at niche markets with unmet medical needs. For more information, please visit http://www.insmed.com.
This release contains forward-looking statements which are made
pursuant to provisions of Section 21E of the Securities Exchange Act of
1934. Investors are cautioned that such statements in this release,
including statements relating to planned clinical study design, regulatory
and business strategies, strategic alternatives, plans and objectives of
management and growth opportunities for existing or proposed products,
constitute forward-looking statements which involve risks and uncertainties
that could cause actual results to differ materially from those anticipated
by the forward-looking statements. The risks and uncertainties include,
without limitation, risks that strategic alternatives may never be
consummated, product candidates may fail in the clinic or may not be
successfully marketed or manufactured, we may lack financial resources to
complete development of product candidates, the FDA may interpret the
results of studies differently than us, compe
|SOURCE Insmed Inc.|
Copyright©2008 PR Newswire.
All rights reserved